LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced the results from a new clinical study evaluating the efficacy of a hydroquinone skin care system (Nu-Derm®), plus tretinoin, in decreasing the severity of melasma, particularly in skin of color patients. This data was presented at the 22nd World Congress of Dermatology (WCD) in May 2011.
